Abstract
In the present study, we aimed to investigate the effects of continuous glucose monitoring (CGM) on blood glucose levels, body weight, blood pressure, and hypoglycaemia in patients with type 2 diabetes mellitus using a meta-analysis of randomized controlled trials (RCTs). A literature search was performed using MEDLINE, Cochrane Controlled Trials Registry, and ClinicalTrials.gov. RCTs using CGM in patients with type 2 diabetes mellitus were then selected. Statistical analysis included calculation of the standardized mean difference (SMD) or risk ratio and 95% confidence intervals (CIs) using a random effects model. After literature search, seven RCTs (669 patients) satisfied the eligibility criteria established herein and were included into the meta-analysis. Compared with the self-monitoring blood glucose group, the CGM group exhibited significantly lower HbA1c levels (SMD, −0.35; 95% CI, −0.59–−0.10; P = 0.006) and shorter time spent with hypoglycaemia (SMD, −0.42; 95% CI, −0.70–−0.13; P = 0.004). Conversely, no differences in body weight and blood pressure were observed between the groups. CGM in patients with type 2 diabetes mellitus could reduce HbA1c levels and time spent with hypoglycaemia. However, because few RCTs were included in this present study and heterogeneity was also noted, care should be taken when interpreting the results.
Highlights
The number of patients suffering from type 2 diabetes mellitus is increasing worldwide, with estimates suggesting that approximately 300 million individuals could develop the disease by 2050 [1, 2]
We aimed to investigate the effects of continuous glucose monitoring (CGM) on blood glucose levels, body weight, blood pressure, and hypoglycaemia in patients with type 2 diabetes mellitus using a meta-analysis of randomized controlled trials (RCTs)
We examined the influence of CGM on blood glucose levels, weight, blood pressure, and frequency of hypoglycaemia in patients with type 2 diabetes mellitus using a meta-analysis of RCTs
Summary
The number of patients suffering from type 2 diabetes mellitus is increasing worldwide, with estimates suggesting that approximately 300 million individuals could develop the disease by 2050 [1, 2]. In many cases, favourable blood glucose control cannot be achieved through the aforementioned therapeutic interventions alone [5, 6]. Self-monitoring blood glucose (SMBG) has been proven to be useful for long-term glycaemic control in patients with type 2 diabetes mellitus [7]. This method places considerable burden on the patient given that performing finger pricking several times per day is troublesome and painful [8]. Understanding detailed blood sugar fluctuations, such as elevated blood glucose after meals or asymptomatic hypoglycaemia, may be difficult [9]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
